Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) Just Landed On The Top Of Paul Prescott’s Radar This Morning
—Thursday, August 6, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At SNOA While It’s Still Early…
August 6, 2026 Dear Reader, Last night we introduced you to Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) — and this morning it’s already at the top of our list. The bell rings in less than 90 minutes. Here is why SNOA has our full focus before the open. On June 30, 2026, SNOA secured a new FDA 510(k) clearance for its Microdacyn® Wound Irrigation Solution — expanding its approved indications, authorizing multiple-use labeling, and adding new packaging configurations including spray and flip-top formats, each with a 24-month shelf life. For a company built around licensing patented HOCl technology to commercial partners, a clearance like this makes the product more attractive to every prospective distributor and private-label customer worldwide. That clearance came roughly two weeks after SNOA reported fiscal year 2026 financial results showing full-year revenues of $19.5M — a 37% increase over the prior year. U.S. revenues grew 117% year-over-year to $5.7M. Q4 revenues hit $5.6M, up 48% from Q4 2025. EBITDA loss improved 66% in Q4 and 38% for the full year. Earlier in 2026, SNOA launched its Advanced Burn Relief Hydrogel into CVS and Walmart stores nationally — its first large-scale OTC burn care placement in major U.S. retail. The company has fewer than 5M shares listed as available to the public. With a float that small, even small shifts in demand could lead to the potential for big swings. SNOA appears to be flying under the radar while currently trending below $1.50. Less than 90 minutes to the bell. Pull up SNOA while it is still early. We will have all eyes on SNOA this morning. 
Here Is What The New Clearance Means For SNOA
The clearance expands the product’s approved uses, authorizes multiple-use labeling, and adds several packaging configurations, including spray and flip-top formats with a 24-month shelf life. For a company whose business model is built on translating patented HOCl technology into commercial licensing and contract manufacturing deals, that kind of regulatory expansion is not simply a product upgrade—it is a more attractive offering for every prospective distributor and private-label customer worldwide. The clearance arrived roughly two weeks after SNOA reported fiscal year 2026 financial results showing total revenues of $19.5M, a 37% increase over the $14.3M recorded in fiscal year 2025. U.S. revenues grew 117% year-over-year to $5.7M, driven by new distributors gaining traction in the domestic market. Q4 2026 revenue reached $5.6M, up 48% from the same period in the prior year. EBITDA loss improved 66% in Q4 and 38% for the full year, a sign that operational discipline is beginning to show up in the financials alongside the revenue expansion. In March 2026, SNOA launched its Advanced Burn Relief Hydrogel into CVS and Walmart stores nationally, marking the company’s first large-scale over-the-counter burn care product placement in major U.S. retail. That followed earlier distribution momentum through Medline Industries, which distributes into hospital systems and home healthcare channels across the United States. The global wound care market was valued at approximately $27B in 2026 and is projected to reach nearly $40B by 2035, expanding at a CAGR of approximately 4.4%, according to Precedence Research. 
That backdrop creates a durable commercial environment for a company that holds 23 FDA 510(k) clearances, manufactures in Mexico, operates European commercial headquarters in the Netherlands, and supports partners in more than 55 countries. HOCl-based wound care has been a growing preference among clinical and consumer end-users for its non-toxic, non-irritating profile—and SNOA has built one of the more defensible HOCl manufacturing and regulatory platforms in the space. We will have all eyes on SNOA tomorrow morning. Take a look at Sonoma Pharmaceuticals before you call it a night. About Sonoma Pharmaceuticals, Inc
Sonoma Pharmaceuticals, Inc., based in Boulder, Colorado, develops and manufactures healthcare products using its patented Microcyn® stabilized hypochlorous acid, or HOCl, technology. HOCl is a substance naturally produced by the human immune system. Sonoma has developed a process that keeps HOCl stable so it can be packaged, shipped, and used in products for wound care, burn care, skin care, eye care, oral care, foot care, animal health, and disinfection. The company generates revenue in three main ways. It develops and manufactures products for partners that sell them under their own brand names, sells products under the Sonoma brand, and licenses its HOCl formulas and regulatory clearances to other companies. This model allows the company to generate revenue from its regulatory portfolio without bearing the full cost of direct consumer marketing at every point of distribution. Sonoma’s manufacturing operation runs out of a high-capacity facility in Guadalajara, Mexico, where the company produces finished goods for partners across its global network. European commercial headquarters are maintained in Roermond, Netherlands, serving distribution relationships across that region. The company supports commercial partners in more than 55 countries, with active expansion of its partner network underway. 
Sonoma offers a wide range of products, including Microdacyn® for wound care, Reliefacyn® Advanced for itching, burns, rashes, and pain, Ocucyn for cleaning the eyelids and eyelashes, MicrocynAH for animal health, Nanocyn for hospital disinfection, Microdacyn60 for oral care, Sinudox for nasal irrigation, and Gramaderm for mild-to-moderate acne. Depending on the product and the country where it is sold, these products may be available by prescription, over the counter, or directly through healthcare offices. As of its most recent annual report, the company held 23 FDA 510(k) clearances. A Sector Built On Chronic Demand Not Market Cycles
The wound care sector is one of the more structurally durable segments in medical devices. Its demand base is not cyclical — it is driven by chronic disease prevalence, an aging global population, and the persistent clinical challenge of infection management in compromised tissue. Diabetic foot ulcers, pressure injuries, venous leg ulcers, and surgical site complications represent a patient population that continues to grow in every major healthcare market, and that population requires ongoing product consumption rather than one-time interventions. North America captured more than 46% of global wound care revenue in 2025, driven by the density of chronic wound patients, a favorable reimbursement environment, and established hospital procurement infrastructure, according to Precedence Research. Asia Pacific is the region flagged for fastest growth over the forecast window — a factor relevant to any company like SNOA that already operates across 55 countries and continues to build its international distribution presence. Within wound care, advanced wound management is the fastest-growing product segment. That category encompasses products that go beyond basic dressings to actively manage the wound environment — HOCl-based solutions fit squarely within this framework. Clinical and consumer awareness of HOCl as an effective, non-toxic wound care agent has grown considerably over the past decade, and the category continues to expand as both healthcare systems and retail buyers seek solutions that are gentle enough for sensitive skin and effective enough for chronic wound protocols. The over-the-counter consumer channel offers an additional path for growth for companies with the regulatory approvals and infrastructure needed to serve it. 
Major U.S. retail placement — through chains like CVS and Walmart — requires both FDA clearance and a manufacturing operation capable of meeting commercial-scale volume requirements. Sonoma has demonstrated both capabilities. Its recent OTC launches position the company to participate in the growing consumer interest in clinically-backed wound and skin care products, an area where branded HOCl formulations have not yet reached their full penetration potential. Recent Milestones
FDA Clearance | June 30, 2026
SNOA received a new FDA 510(k) clearance for Microdacyn® Wound Irrigation Solution, expanding approved indications to include Stage I–IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, abrasions, minor burns, and daily skin maintenance including eyelid, eyelash, and facial care. The clearance also authorized multiple-use labeling and four new packaging configurations — including 4 oz, 8 oz, 16 oz, and 34 oz PET bottles with flip-top caps and 4 oz spray formats — each with a 24-month shelf life. Management framed the clearance as expanding the commercial attractiveness of the product for prospective distributors and private-label customers. 
Financial Results | June 16, 2026
SNOA reported full-year fiscal 2026 revenues of $19.5M, a 37% increase over FY2025. U.S. revenues grew 117% year-over-year to $5.7M. Q4 2026 revenues reached $5.6M, up 48% from Q4 2025, with Q4 U.S. revenues up 194%. EBITDA loss improved 66% in Q4 and 38% for the full fiscal year. Cash and equivalents stood at $2.4M at March 31, 2026. Retail Expansion | March 24, 2026
SNOA announced the national U.S. retail launch of its Advanced Burn Relief Hydrogel in CVS and Walmart stores, marking the company's first large-scale OTC burn care product placement in major retail. The product is distributed through a U.S.-based partner and is indicated for minor burns and skin irritations. Product Launch | March 18, 2026
SNOA announced the launch of a new dermatology product line under Person & Covey's Aquanil brand for sensitive skin, extending the company's reach into the established dermatology and personal care distribution channel. Leadership | January 28, 2026
SNOA announced a new Board Director and a new Senior Vice President of Regulatory, Quality and Product Development, reinforcing its regulatory and quality leadership infrastructure as the company continues to expand its clearance portfolio. Clinical Recognition | November 13, 2025
The National Rosacea Society awarded Reliefacyn® Advanced its Seal of Acceptance, following a National Psoriasis Foundation Seal of Recognition awarded in August 2025. Both designations provide independent clinical credibility for HOCl-formulated consumer dermatology products within large chronic skin condition communities. 7 Reasons Why SNOA Is Topping This Morning’s Watchlist —Thursday, August 6, 2026…
1. Small Float: With fewer than 5M shares listed as available to the public, SNOA’s small float could witness the potential for big moves if demand begins to shift.
2. Fresh FDA Clearance: A June 2026 FDA decision expanded the approved uses, multiple-use labeling, packaging formats, and shelf life for SNOA’s Microdacyn® Wound Irrigation Solution. 3. Revenue Expansion: Full-year fiscal 2026 revenue increased 37% to $19.5M, while SNOA’s U.S. revenue rose 117% to $5.7M. 4. Strong Fourth Quarter: Q4 revenue climbed 48% to $5.6M, with SNOA also reporting a 194% increase in quarterly U.S. revenue from the prior-year period. 5. Major Retail Reach: National placement of Advanced Burn Relief Hydrogel in CVS and Walmart gave SNOA its first large-scale OTC burn care presence in major U.S. retail. 6. Broad FDA Portfolio: With 23 FDA 510(k) clearances, SNOA has products spanning wound care, burn care, dermatology, eye care, oral care, animal health, and disinfection. 7. Global Commercial Footprint: Manufacturing in Mexico, European headquarters in the Netherlands, and partners in more than 55 countries give SNOA an established international platform. Take A Look At SNOA While It’s Still Early…
Sonoma Pharmaceuticals enters this week with a fresh FDA clearance in hand, a fiscal year that showed 37% revenue growth, a domestic U.S. business that more than doubled year-over-year, and a share structure compact enough that any meaningful shift in attention tends to register in the price. The Microdacyn® expansion adds configuration and claim breadth to a product that already serves one of the most durable clinical demand categories in healthcare. The company has been quiet in the broader narrative for most of this year—but the fundamentals have not been quiet. The gap between those two things is exactly what we look for when we scan for names worth putting on the radar. We have all eyes on SNOA this morning. Take a look at Sonoma Pharmaceuticals while it’s still early. Also, keep a look out for my next update. Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter |
0 التعليقات:
إرسال تعليق